Boehringer Ingelheim and Microsoft explore AI-based clinical development
- The collaboration will investigate Digital Patient Twins for clinical development, beginning with lung health.
- Research will cover disease-progression and outcome modelling, plus advanced trial simulation.
- The partners will assess whether synthetic or hybrid control arms could reduce the number of patients needed in control groups.
- Potential co-development projects include Animal Health, business processes and technology infrastructure.
Clinical development research
Boehringer Ingelheim and Microsoft will investigate Digital Patient Twins—computational representations of individual patients that use clinical and other relevant data to model disease progression and potential outcomes under different scenarios.
The research will examine disease-progression and predictive outcome modelling, as well as advanced trial simulation. It will assess whether synthetic or hybrid control arms could be used as alternatives to conventional clinical control groups. The partners say these approaches may help reduce control-group sizes, speed evidence generation and improve trial design.
They will assess scientific and technical feasibility through modelling, prototyping and evidence generation across multiple disease and therapeutic areas, starting with lung health. The work must meet scientific quality, patient-safety and regulatory requirements.
Wider collaboration
The partnership also covers security and datacenter modernization. The companies are exploring potential co-development projects in Animal Health, business processes and technology infrastructure.
Boehringer Ingelheim is also working to embed AI across its value chain, building on a Microsoft Copilot deployment and combining employee access with role-based applications, skills development, governance and secure technology foundations.
Source: Boehringer Ingelheim